Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK F1174C |
Therapy | Cyclophosphamide + Doxorubicin + Lorlatinib + Vincristine Sulfate |
Indication/Tumor Type | neuroblastoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174C | neuroblastoma | predicted - sensitive | Cyclophosphamide + Doxorubicin + Lorlatinib + Vincristine Sulfate | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Lorbrena (lorlatinib), Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), and Oncovin (vincristine) resulted in modest inhibition of tumor growth in a patient-derived xenograft (PDX) model of neuroblastoma harboring ALK F1174C (PMID: 36602782). | 36602782 |
PubMed Id | Reference Title | Details |
---|---|---|
(36602782) | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. | Full reference... |